Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Merck
Cipla
AstraZeneca
Healthtrust

Generated: August 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,815,246

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,815,246
Title:Fc receptor binding proteins
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
Inventor(s): TenHoor; Christopher (Hopkinton, MA), Muruganandam; Arumugam (Bangalore, IN), Ladner; Robert Charles (Ijamsville, MD), Wood; Clive (Boston, MA), Bitonti; Alan J. (Acton, MA), Stattel; James (Hagerstown, MD), McDonnell; Kevin (Waltham, MA), Liu; Liming (Upper Dublin, PA), Dumont; Jennifer (Groton, MA), Sato; Aaron K. (Richmond, CA), Viswanathan; Malini (Burlington, MA)
Assignee: Dyax Corp. (Cambridge, MA) Syntonix Pharmaceuticals, Inc. (Waltham, MA)
Application Number:13/617,498
Patent Claims:1. A method of modulating the half-life/levels of circulating IgG in a subject in need thereof, the method comprising: administering to the subject in need thereof an effective amount of an antibody that binds human FcRn, wherein the antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, and wherein the HC comprises: a HC CDR1 comprising an amino acid sequence EYAMG (SEQ ID NO: 144) or VYAMG (SEQ ID NO:156), a HC CDR2 comprising an amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 145) or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 comprising an amino acid sequence LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or LAIGDSY (SEQ ID NO:176); and the LC comprises: a LC CDR1 comprising an amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141), a LC CDR2 comprising an amino acid sequence GDSQRPS (SEQ ID NO: 142), and a LC CDR3 comprising an amino acid sequence CSYAGSGIYV (SEQ ID NO: 143).

2. The method of claim 1, wherein the antibody is administered in an amount effective to reduce the binding of IgG to FcRn in the subject.

3. The method of claim 1, wherein the antibody is administered in an amount effective to reduce the half-life/levels of circulating IgG in the subject.

4. The method of claim 1, wherein the HC comprises: (i) a HC CDR1 of EYAMG (SEQ ID NO:144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LSTGELY (SEQ ID NO:146); (ii) a HC CDR1 of VYAMG (SEQ ID NO:156), a HC CDR2 of SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 of LSIRELV (SEQ ID NO:158); (iii) a HC CDR1 of VYAMG (SEQ ID NO:156), a HC CDR2 of SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 of LSIVDSY (SEQ ID NO:164); (iv) a HC CDR1 of EYAMG (SEQ ID NO:144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LSLGDSY (SEQ ID NO:170); or (v) a HC CDR1 of EYAMG (SEQ ID NO:144), a HC CDR2 of SIGSSGGQTKYADSVKG (SEQ ID NO:145), and a HC CDR3 of LAIGDSY (SEQ ID NO:176); and the LC comprises: a LC CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141), a LC CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO:142), and a LC CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO:143).

5. The method of claim 1, wherein the amount of the antibody is effective in reducing the concentration of undesired antibodies in the subject.

6. The method of claim 5, wherein the undesired antibody is administered to the subject.

7. The method of claim 6, wherein the undesired antibody is natalizumab.

8. The method of claim 1, wherein the amount of the antibody is effective in modulating an FcRn activity in the subject.

9. The method of claim 8, wherein the activity of the FcRn is binding of the FcRn to an endogenous Ig.

10. The method of claim 8, wherein the activity of the FcRn is binding of the FcRn to a therapeutic antibody.

11. The method of claim 1, wherein the subject has or is suspected of having an autoimmune disorder.

12. The method of claim 11, wherein the autoimmune disorder is rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Myasthenia Gravis (MG), Graves Disease, Idiopathic Thrombocytopenia Purpura (ITP), Guillain-Barre Syndrome, autoimmune myocarditis, Membrane Glomerulonephritis, Type I diabetes, multiple sclerosis, Raynaud's syndrome, autoimmune thyroiditis, gastritis, Celiac Disease, Vitiligo, Hepatitis, primary biliary cirrhosis, inflammatory bowel disease, spondyloarthropathies, experimental autoimmune encephalomyelitis, immune neutropenia, sarcoidosis, polymyositis, polyarteritis, cutaneous vasculitis, pemphigus, pemphigoid, Goodpasture's syndrome, Kawasaki's disease, systemic sclerosis, anti-phospholipid syndrome, or Sjogren's syndrome.

Details for Patent 8,815,246

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Dyax Corp. (Cambridge, MA) Syntonix Pharmaceuticals, Inc. (Waltham, MA) 2028-04-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,815,246

Country Patent Number Publication Date
South Africa 201007873 Feb 29, 2012
World Intellectual Property Organization (WIPO) 2009131702 Feb 18, 2010
World Intellectual Property Organization (WIPO) 2009131702 Oct 29, 2009
World Intellectual Property Organization (WIPO) 2009131702 Sep 23, 2010
United States of America 2009324614 Dec 31, 2009
United States of America 2013045218 Feb 21, 2013
United States of America 2013078262 Mar 28, 2013
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Boehringer Ingelheim
Fuji
Healthtrust
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.